Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease

Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease - TREAT-CAD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025571

Enrollment

1000

Registered

2017-01-07

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

High level-control group serum EPA/AA&gt

or=0.4 EPA-group serum EPA/AA&lt

0.4 with 1800mg of purified EPA administration daily non-EPA-group serum EPA/AA&lt

0.4 with 1800mg of purified EPA administration daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Coronary artery disease

Exclusion criteria

Exclusion criteria: patient with current bleeding patients with bleeding tendency and hemorrhagic diathesis patient with an elective surgical treatment Patient judged as inappropriate by a physician

Design outcomes

Primary

Measure	Time frame
the incidence cardiovascular event after an intervention at least 1 year ago	—

Secondary

Measure	Time frame
the incidence of all douse death, stroke, hospitalization due to congestive heart failure and/or composite end point of all after an intervention at least 1 year ago	—

Countries

Japan

Contacts

Public ContactShichiro Abe

Dokkyo Medical University Department of cardiovascular medicine

abenana@dokkyomed.ac.jp0282-87-2146

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026